The Las Vegas showgirl was beautiful, majestic, and larger than life. In full feathers and heels, a showgirl could measure 10 feet tall. She exuded poise and panache, and her revealing costume was bedecked in glimmering Parisian crystals and expensive fur. She was a city icon who helped Las Vegas become the Entertainment Capital of the World.The showgirl is a distant memory for most, but there is hope that she will one day return to the stage.
AXS-05 Meets Primary End Point in Phase 3 Trial of Alzheimer Agitation
Newly announced findings from the phase 3 ACCORD trial (NCT04797715) showed that AXS-05 (Axsome Therapeutics), a novel, investigational n-methyl-D-aspartate (NMDA) receptor antagonist, met its primary end point of statistically significant delay in time to relapse and preventing relapse of agitation in patients with Alzheimer disease (AD) agitation.1
Biopharmaceutical company Axsome Therapeutics Inc. (AXSM:NASDAQ), which is focused on developing new medicines for use in the treatment of central nervous system (CNS) disorders, today announced that "AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes in Alzheimer's Disease Agitation) Phase 3 trial, by substantially and statistically significantly delaying the time to relapse and preventing relapse of agitation in patients with Alzheimer's disease, as compared to placebo."
Guillermo M. Jodra (World Languages and Cultures), presented a paper titled, "Sparta and the Athenian Mirage," on November 13 at the Pacific Ancient and Modern Language Association Conference in Los Angeles, CA.